{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-24-000006","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.280244+00:00","generated_at":"2026-05-31T10:52:00.902668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Quanterix Q2 revenue up 11% to $34.4M; net loss widens to $9.5M; cuts FY2024 revenue guidance","bullets":["Revenue $34.4M (+10.8% YoY); GAAP gross margin 58.3% vs 61.7% prior year.","Net loss $9.5M, up $3.4M from prior year; cash usage $5.1M in quarter.","Revised FY2024 revenue guidance to $134M-$138M from $139M-$144M due to constrained capital environment.","Cash usage for 2024 now expected at higher end of $25M-$30M range.","New Alzheimer's diagnostic partnerships with Mt. Sinai, Banner Health, UCSF, and KingMed Diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-24-000006","json":"https://secwatch.observer/filing/0001503274-24-000006.json","markdown":"https://secwatch.observer/filing/0001503274-24-000006.md","text":"https://secwatch.observer/filing/0001503274-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327424000006/0001503274-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327424000006/qtrx-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:52:00.902668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}